Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study.

Javier C AnguloJ P Ciria SantosA Gómez-CaamañoR Poza de CelisJ L González SalaJ M García GarzónJuan Antonio Galán-LlopisM Pérez SampietroV PerrotJ Planas Morinnull null

Published in: World journal of urology (2022)

The proportion of metastatic patients developing CRPC after 3 years of treatment with LHRHa is consistent with what has been previously described in the literature. In addition, this study provides new findings on CRPC in non-metastatic patients. Concomitant medication and nadir PSA are statistically significant predictive factors for the time to diagnosis of CRPC, the nadir PSA being the strongest predictor.

Keyphrases

prostate cancer
end stage renal disease
squamous cell carcinoma
small cell lung cancer
chronic kidney disease
systematic review
peritoneal dialysis
prognostic factors
emergency department
healthcare
patient reported outcomes
combination therapy
replacement therapy